
Advancing Recognition, Intervention, and Assessment of ARIA to Optimize the Therapeutic Potential of Anti-Amyloid Therapies for Patients with Alzheimer’s Disease
Region: Asia | Target Audience: Neurologists and Psychiatrists
This enduring activity brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.
RELEASED DATE: March 19, 2026
EXPIRATION DATE: March 19, 2027

Advancing Recognition, Intervention, and Assessment of ARIA to Optimize the Therapeutic Potential of Anti-Amyloid Therapies for Patients with Alzheimer’s Disease
Region: Asia | Target Audience: PCPs, Emergency Physicians, & Infusion/Triage Nurses
This enduring activity brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.
RELEASED DATE: May 15, 2026
EXPIRATION DATE: May 15, 2027

Advancing Recognition, Intervention, and Assessment of ARIA to Optimize the Therapeutic Potential of Anti-Amyloid Therapies for Patients with Alzheimer’s Disease
Region: Europe | Target Audience: PCPs, Emergency Physicians, & Infusion/Triage Nurses
This enduring activity brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.
RELEASED DATE: May 15, 2026
EXPIRATION DATE: May 15, 2027

Advancing Recognition, Intervention, and Assessment of ARIA to Optimize the Therapeutic Potential of Anti-Amyloid Therapies for Patients with Alzheimer’s Disease
Target Audience : Neurologists and Psychiatrists
This brief Snapshot, presented by a leading global expert, delivers practical, evidence-based guidance for recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through an engaging whiteboard animation, expert insights, and case-based discussions, learners will strengthen their ability to identify ARIA, interpret clinical and imaging findings, and implement appropriate monitoring and management strategies. The program also highlights best practices for identifying patient-specific risk factors, applying guideline-informed approaches to mitigate ARIA risk, and fostering multidisciplinary collaboration to support the safe, effective, and patient-centered use of anti-amyloid therapies in clinical practice.
RELEASED DATE: August 7, 2026
EXPIRATION DATE: August 7, 2027

Advancing Recognition, Intervention, and Assessment of ARIA to Optimize the Therapeutic Potential of Anti-Amyloid Therapies for Patients with Alzheimer’s Disease
Region: United States | Target Audience: PCPs, Emergency Physicians, & Infusion/Triage Nurses
This enduring activity brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.
RELEASED DATE: May 15, 2026
EXPIRATION DATE: May 15, 2027

Advancing Recognition, Intervention, and Assessment of ARIA to Optimize the Therapeutic Potential of Anti-Amyloid Therapies for Patients with Alzheimer’s Disease
Region: Asia | Target Audience: Radiologists and Neuroradiologists
This enduring activity brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.
RELEASED DATE: May 08, 2026
EXPIRATION DATE: May 08, 2027

Advancing Recognition, Intervention, and Assessment of ARIA to Optimize the Therapeutic Potential of Anti-Amyloid Therapies for Patients with Alzheimer’s Disease
Region: Europe | Target Audience: Radiologists and Neuroradiologists
This enduring activity brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.
RELEASED DATE: May 08, 2026
EXPIRATION DATE: May 08, 2027

Advancing Recognition, Intervention, and Assessment of ARIA to Optimize the Therapeutic Potential of Anti-Amyloid Therapies for Patients with Alzheimer’s Disease
Region: United States | Target Audience: Radiologists and Neuroradiologists
This enduring activity brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.
RELEASED DATE: May 08, 2026
EXPIRATION DATE: May 08, 2027

Advancing Recognition, Intervention, and Assessment of ARIA to Optimize the Therapeutic Potential of Anti-Amyloid Therapies for Patients with Alzheimer’s Disease
Region: United States | Target Audience: Neurologists and Psychiatrists
This enduring activity brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.
RELEASED DATE: March 19, 2026
EXPIRATION DATE: March 19, 2027

Advancing Recognition, Intervention, and Assessment of ARIA to Optimize the Therapeutic Potential of Anti-Amyloid Therapies for Patients with Alzheimer’s Disease
Region: Europe | Target Audience: Neurologist and Psychiatrists
This enduring activity brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.
RELEASED DATE: March 19, 2026
EXPIRATION DATE: March 19, 2027








































































